Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer

Molecular Therapy

Volumn 13, Issue 4, 2006, Pages 716-728

  Ayala, Gustavo ^a   Satoh, Takefumi ^a   Li, Rile ^a   Shalev, Moshe ^a   Gdor, Yehoshua ^a   Aguilar Cordova, Estuardo ^b   Frolov, Anna ^a   Wheeler, Thomas M ^a   Miles, Brian J ^a   Rauen, Kate ^c   Teh, Bin S ^a   Butler, Brian E ^a   Thompson, Timothy C ^a   Kadmon, Dov ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Advantagene ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Car; Gene therapy; HSV tk; Immune response; Microvessel density; Necrosis; Prostate cancer

Indexed keywords

CD8 ANTIGEN; CIPROFLOXACIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GANCICLOVIR; GENTAMICIN; INTERLEUKIN 12; PROSTATE SPECIFIC ANTIGEN; THYMIDINE KINASE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL INFECTION; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXIC T LYMPHOCYTE; FEVER; GENE EXPRESSION; GENE THERAPY; GLEASON SCORE; HERPES SIMPLEX VIRUS; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LEUKOPENIA; LIVER DYSFUNCTION; MALE; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; RECURRENCE RISK; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TUMOR VOLUME;

AGED; ANTIVIRAL AGENTS; APOPTOSIS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYTOPATHOGENIC EFFECT, VIRAL; FOLLOW-UP STUDIES; GANCICLOVIR; GENE THERAPY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; THYMIDINE KINASE; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

ADENOVIRIDAE; BACTERIA (MICROORGANISMS); COXSACKIEVIRUS; SIMPLEXVIRUS;

EID: 33645510632     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.11.022     Document Type: Article

References (31)

1. G.W. Jones et. al. Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990 J. Am. Coll. Surg. 180 1995 545-554
2. G.P. Murphy C. Mettlin H. Menck D.P. Winchester and A.M. Davidson National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer J. Urol. 152 5 Pt 2 1994 1817-1819
3. T.C. Thompson et. al. In situ gene therapy for prostate cancer: immunomodulatory approaches Expert Opin. Biol. Ther. 1 2001 481-495
4. M. Shalev T.C. Thompson D. Kadmon G. Ayala K. Kernen and B.J. Miles Gene therapy for prostate cancer Urology 57 2001 8-16
5. B.J. Miles et. al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy Hum. Gene Ther. 12 2001 1955-1967
6. G. Ayala et. al. Cytopathic effect of in situ gene therapy in prostate cancer Hum. Pathol. 31 2000 866-870
7. K.A. Rauen et. al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy Cancer Res. 62 2002 3812-3818
8. S. Loimas M.R. Toppinen T. Visakorpi J. Janne and J. Wahlfors Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy Cancer Gene Ther. 8 2001 137-144
9. J. Cheon H.K. Kim D.G. Moon D.K. Yoon J.H. Cho and S.K. Koh Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: Changes in tumour cell proliferative activity BJU Int. 85 2000 759-766
10. M.W. Kattan J.A. Eastham A.M. Stapleton T.M. Wheeler and P.T. Scardino A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J. Natl. Cancer Inst. 90 1998 766-771
11. A. Gotoh et. al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer J. Urol. 160 1998 220-229
12. D.S. O'Keefe et. al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer Prostate 45 2000 149-157
13. K.S. Koeneman et. al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis World J. Urol. 18 2000 102-110
14. T.L. Timme S.J. Hall R. Barrios S.L. Woo E. Aguilar-Cordova and T.C. Thompson Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice Cancer Gene Ther. 5 1998 74-82
15. M. Shalev et. al. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer J. Urol. 163 2000 1747-1750
16. J. Folkman The role of angiogenesis in tumor growth Semin. Cancer Biol. 3 1992 65-71
17. A.F. Junod H. Petersen and L. Jornot Thymidine kinase, thymidylate synthase, and endothelial cell growth under hyperoxia J. Appl. Physiol. 62 1987 10-14
18. L.F. Xu D.H. Xu K. Ge Z.C. Zheng L.Y. Sun and X.Y. Liu The use of suicide gene systems in vascular cells in vitro Cell Res. 8 1998 73-78
19. P.G. Steg et. al. Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy Circulation 96 1997 408-411
20. M.W. Chang et. al. Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery Mol. Med. 1 1995 172-181
21. T. Tanaka Effect of adenoviral-mediated thymidine kinase transduction and ganciclovir therapy on tumor-associated endothelial cells Neurol. Med. Chir. (Tokyo) 37 1997 730-737 (discussion 737-738)
22. T. Tanaka Y. Cao J. Folkman and H.A. Fine Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA Cancer Res. 58 1998 3362-3369
23. S.J. Hall M.A. Sanford G. Atkinson and S.H. Chen Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer Cancer Res. 58 1998 3221-3225
24. S.W. Sukin et. al. In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer Mol. Ther. 3 2001 500-506
25. S.J. Hall S.E. Mutchnik S.H. Chen S.L. Woo and T.C. Thompson Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer Int. J. Cancer 70 1997 183-187
26. J.A. Eastham et. al. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models Hum. Gene Ther. 7 1996 515-523
27. J.D. Eaton et. al. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques Gene Ther. 8 2001 557-567
28. W. Hassan M.A. Sanford S.L. Woo S.H. Chen and S.J. Hall Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer World J. Urol. 18 2000 130-135
29. S.J. Hall et. al. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer Cancer Gene Ther. 6 1999 54-63
30. B.S. the Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer - A preliminary report Int. J. Radiat. Oncol. Biol. Phys. 51 2001 605-613
31. G. Atkinson and S.J. Hall Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer Urology 54 1999 1098-1104